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Renal dysfunction is common during episodes of acute decompensated heart failure, and historical data
indicate that the mean creatinine level at admission has risen in recent decades. Different mechanisms
underlying this change over time have been proposed, such as demographic changes, hemodynamic and
neurohumoral derangements and medical interventions. In this setting, various strategies have been proposed
for the prevention of renal dysfunction with heterogeneous results. In the present article, we review and discuss
the main aspects of renal dysfunction prevention according to the different stages of heart failure.
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& SCOPE OF THE PROBLEM
Renal dysfunction is common during episodes of acute
decompensated heart failure and is found in up to 64% (1) of
patients at hospital admission. Historical analysis indicates
that the mean creatinine level at admission has risen in recent
decades (2). Different mechanisms underlying this change
over time have been proposed. First, as a consequence of
better clinical care and surgical interventions, there has been
a shift towards a larger number of patients with advanced
heart failure (3), and in these circumstances, patients tend to
be older and to accumulate risk factors, such as hypertension
and diabetes mellitus (4,5). Additionally, hemodynamic and
neurohumoral derangements are exacerbated during epi-
sodes of decompensation and further contribute to de novo
kidney dysfunction or the worsening of a chronic kidney
disease. Medical interventions may also produce a reduction
of the glomerular filtration rate (GFR) by reducing blood
pressure, inducing hypovolemia or reducing the glomerular
perfusion pressure.
However, in biological phenomena, epidemiological
associations may not reflect causality, and whether worsen-
ing renal function itself contributes to the increased
mortality or whether it merely serves as a marker of a more
severe disease remains unclear. Conditions such as diabetes
and hypertension may offer an epidemiological link that
associates heart failure and kidney disease. Additionally,
kidney disease and heart failure have been suggested not to
represent single clinical entities but rather to represent
manifestations of a broader vascular injury associated with
aging that affects multiple organs (6).
In this setting, various strategies have been proposed for
the prevention of renal dysfunction with heterogeneous
results. In the present article, we review and discuss the
main aspects of renal dysfunction prevention according to
the different stages of heart failure.
Definitions
In 2005, the American Heart Association and the
American College of Cardiology proposed a staging
classification that incorporated a conceptual change relative
to the classical definition of heart failure syndrome, which
dealt almost exclusively with symptomatic patients. The
new categorization incorporated stages A and B, with stage
A identifying patients at risk for heart failure but without
structural heart disease or symptoms of the syndrome and
stage B encompassing patients with structural heart disease
but without symptoms of heart failure. During the course of
the syndrome, patients may experience a decrease in kidney
function, and strategies for treatment and prevention should
take into consideration the burden of epidemiological
characteristics and the presence of risk factors in the context
of the hemodynamic and neurohumoral events associated
with heart failure syndrome.
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Patients with heart failure who are experiencing a
decrease in renal function usually have peculiar character-
istics, including manifestations of hypervolemia, oliguria
and diuretic resistance, in a clinical picture frequently
referred to as cardiorenal syndrome. Cardiorenal syndrome
has been suggested to encompass disorders of the heart and
kidneys, either acute or chronic, in such an association that
dysfunction in one organ may induce acute or chronic
dysfunction of the other. A categorization into five different
types has been proposed (7). Although such a categorization
may be helpful in identifying patients with different
pathophysiological mechanisms, it includes a heteroge-
neous group of clinical presentations or diagnoses under
the same definition and adds little value to the care of
patients with a condition in which the mechanisms remain
largely unknown and for which a precise diagnosis may still
be elusive in clinical practice. The AKIN and RIFLE criteria
have been proposed to stratify patients at risk for the
occurrence of renal dysfunction (Figure 1). However, it
should be acknowledged that these criteria are mostly
derived from cohorts of patients in heterogeneous clinical
conditions and represent a general approach to critically ill
patients that including cardiac surgery patients, burn
patients and liver and bone marrow transplantation
patients.
Furthermore, a subset of patients who experience an
increase of 0.3-0.5 mg/dL in serum creatinine or a decrease
in glomerular filtration rate (GFR) of 9-15 ml/min during
admission has been recognized as being at increased risk for
renal dysfunction (8,9). Different biomarkers have been
suggested for the diagnosis of renal dysfunction in the
setting of heart failure (Table 1).
Pathophysiological aspects
Classically, the occurrence of renal dysfunction in patients
with heart failure has been attributed to a low-flow state in
which the decline in glomerular filtration rate is directly
determined by reduced cardiac output. Some indirect
evidence supports this theory, especially the occurrence of
neurohumoral phenomena in patients with heart failure that
are precipitated by renal hypoperfusion; in addition, clinical
experience has indicated that interventions directed
towards increasing cardiac output often restore organ
perfusion, as indicated by clinical parameters such as urine
output and mental status. Clinically, worsening renal
function typically occurs within days of hospitalization,
which suggests a direct causative effect of the hemodynamic
derangement observed when initiating treatment for acute
decompensated heart failure (ADHF), and patients with
progressive pump failure or cardiogenic shock often
develop progressive renal impairment that is reversible
with advanced support.
However, data from clinical trials have challenged this
rationale. The ESCAPE trial tested the influence of a
pulmonary artery catheter–guided therapy in individuals
with acute decompensated heart failure and found no
correlation between the baseline renal function and cardiac
index (10). Furthermore, an improvement in the cardiac
index did not result in improved renal function. This notion
is additionally supported by other investigations that
showed that an improved cardiac index or decreased
pulmonary capillary wedge pressure failed to predict
improvement in renal function (11). Data from the
ADHERE registry indicated that most patients with acute
decompensated heart failure present with elevated, rather
than low, blood pressure (12) and that the incidence of
worsening renal function is similar among patients with
Figure 1 - The Acute Kidney Injury Network and Risk, Injury, Failure, Loss, and End-stage kidney disease definitions.
Table 1 - Biomarkers in heart failure.
GLOMERULAR FUNCTION TUBULOINTERSTITIAL FUNCTION
CREATININE NAG
GFR ESTIMATION NGAL
BUN INTERLEUKIN 18,
CYSTATIN C KIDNEY INJURY MOLECULE 1
ALBUMINURIA FATTY ACID BINDING PROTEIN
URINARY EXOSOMES
BUN: blood urea nitrogen; GFR: glomerular filtration rate; NAG: N-ACETYL-
B-D-GLUCOSAMINIDASE; NGAL: NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN.
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reduced or preserved systolic function (13). Given these
findings, other mechanisms have been proposed.
An alternative explanation could involve a redistribution
of blood from arterial to venous circulation that leads to an
effective reduction in renal blood flow. The resulting
reduction in arterial effective volume can result in increased
sodium and water absorption through stimulation of the
sympathetic nervous system, the renin-angiotensin-aldos-
terone system and vasopressin secretion to preserve renal
perfusion and the renal filtration fraction. However, such
mechanisms are often difficult to demonstrate in individual
patients at the bedside.
Modifications of transrenal perfusion pressure have
increasingly received attention. Transrenal perfusion pres-
sure is calculated as the mean arterial pressure minus the
central venous pressure; therefore, for a patient with volume
overload and heart failure, the combination of increased
central venous pressure with low systemic pressuremay lead
to a severe compromise of the net renal perfusion pressure.
Systemic pressure may be reduced by a decrease in cardiac
output and hypotension; additionally, drugs currently used
to treat heart failure patients may potentiate these effects. For
example, diuretics may cause hypovolemia, and drugs that
inhibit the angiotensin systemmay induce vasodilation of the
efferent circulation and reduction in the glomerular perfu-
sion pressure. Because the kidney is an encapsulated organ,
when renal congestion occurs, the increased venous pressure
may distend the venules surrounding the distal ends of the
tubules, which can obliterate the lumen of the tubule (14).
Other studies have simply suggested that the increased
central venous pressure could be transmitted back to the
renal veins, thereby causing an increase in the renal
interstitial pressure (15,16). This possibility is reinforced by
the observation that intrarenal and systemic angiotensin II
concentrations increase with increasing renal venous pres-
sure (17,18). Elevation of renal venous pressure from the
extrinsic compression of the veins has also been suggested as
a mechanism contributing to reduced renal function in
patients with ascites (19). Non-hemodynamic mechanisms
are also involved. Hyperactivation of the neurohumoral and
inflammatory axes has been associated with progression or
renal and cardiac dysfunction. The activation of RAAS and
SNS induces increased afterload, myocardial oxygen con-
sumption, sodium retention and ventricular remodeling and
is associated with worse outcomes among patients with heart
failure. Accordingly, the activation of these systems may also
contribute to the acceleration of renal disease, as indicated by
the positive effects of RAAS blockade on renal function in
patients with hypertension and diabetes. However, these
effects are likely mediated by endothelial dysfunction,
oxidative stress, fibrosis and inflammation (20).
Preventive measures
Despite the recognition of the epidemiological and
prognostic relevance of renal dysfunction in patients with
decompensated heart failure and all of the efforts directed to
the discovery of novel and more accurate methods for its
diagnosis, few specific interventions are currently available
for the prevention of renal dysfunction in this setting. Most
of bedside protocols are based on experimental data or on
data derived from other clinical conditions. We will briefly
review the general approaches currently available and some
specific interventions currently proposed or under investi-
gation, with a focus on the concept that heart failure is a
progressive condition and that interventions should be
guided by disease stage, patient clinical presentation and
the presence of co-morbidities (Figure 2).
General approach
As discussed above, extreme variations in volume can
reduce the GFR. In hypovolemia, GFR can be reduced by the
reduction of effective plasmatic volume and renal hypoper-
fusion. In contrast, hypervolemic patients may have impaired
renal function because of renal venous congestion, reduced
renal perfusion pressure or renal compression. Therefore,
intense and sudden variations in the plasmatic volume of
patients with decompensated heart failure should be strongly
avoided. Thus, excessive diuretic therapy has traditionally
been seen as deleterious, and in fact, reduced volume has
been described in patients with chronic heart failure under
diuretic therapy. However, transient elevations in creatinine
(possibly associated with modifications of plasmatic volume
and blood pressure) have been considered as common in
patients with decompensated heart failure and thus con-
sidered to not carry the same prognostic significance as
persistent elevations, especially in patients with predominant
right ventricular failure who show improvements in con-
gestive phenomena (21). Additionally, other interventions
currently considered to be standard for the treatment of acute
decompensated heart failure may have deleterious effects on
renal function. Angiotensin-converting enzyme (ACE) inhi-
bitors and angiotensin receptor blockers can decrease
filtration pressure within the glomerulus by inducing
systemic hypotension and predominant vasodilation of the
glomerular efferent arteriole. Although ACE inhibitors and
ARBs remain a mainstay for the treatment of patients with
chronic heart failure, their utility during episodes of
decompensation has not been clearly demonstrated, and
current guidelines do not support the interruption of therapy
with ACE inhibitors and ARBs during episodes of acute
decompensated heart failure. The influence of beta-blockers
on renal function is much less understood. A small study
suggested that the initiation of beta-blocker therapy was
associated with preserved renal function in heart failure
patients with a lower baseline GFR but not in those with a
higher baseline GFR (22), although these results have yet to
be confirmed. Finally, small retrospective studies have
suggested that spironolactone may increase creatinine levels
(23,24) and should be used cautiously in patients with
reduced GFR.
During episodes of acute decompensation, invasive
interventions are often required, and clinicians should be
aware of the possibility of contrast-induced nephropathy
(CIN). Recommendations for the prevention of CIN have
been published (25), and additional care should be taken to
avoid congestive phenomena during pre-procedure hydra-
tion. Frequently, a dose reduction or cessation of the
diuretic therapy is performed in place of active intravenous
hydration. As generally recommended for patients with
chronic heart failure, nonsteroidal anti-inflammatory drugs
(NSAIDs) should not be used during an episode of acute
decompensation, as NSAIDs induce decreases in prosta-
glandin E2, which leads to increased sodium and water
reabsorption that can result in weight gain and edema. As
noted, in individuals with decreased circulating volume,
vasodilatory prostaglandins are produced by the kidneys to
offset other vasoconstricting autacoids. In a clinical setting
in which the renal blood flow depends on prostaglandin
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synthesis, NSAIDs can significantly decrease renal blood
flow, with resultant acute renal failure (26).
Specific interventions
Statins. Data from studies in patients with chronic
kidney disease suggest that statins may preserve renal
function (27). An analysis of the CARE (28) study
demonstrated a significant difference in the rate of decline
with pravastatin in individuals with severe CKD at baseline
relative to the placebo. In the Greek Atorvastatin and
Coronary Heart Disease Evaluation (GREACE) study (29),
the effect of atorvastatin administered at a dose 10 to
80 mg/day on renal function was compared with the ‘‘usual
care’’ in previously untreated dyslipidemic patients with
coronary heart disease. At the end of the study, creatinine
clearance had increased by 12% in the atorvastatin group
and 4.9% in the ‘‘usual care’’ patients. In a subanalysis of the
Treating to New Targets (TNT) study (30), the effect of
intensive lipid reduction on renal function using 10 mg
versus 80 mg of atorvastatin in patients with coronary heart
disease was evaluated. The expected 5-year decline in renal
function was not observed in this study, and the estimated
GFR improved in both TNT treatment groups but was
significantly greater with atorvastatin at 80 mg than at
10 mg, which suggests a dose-related benefit. Additionally,
a meta-analysis of 13 small prospective, controlled trials
examining the effect of statins on renal function showed that
treatment with statins reduced the rate of decline in the GFR
with a possible trend towards proteinuria reduction (2,31).
However, some studies with rosuvastatin indicate a possible
negative effect on renal function and proteinuria. The GISSI-
HF trial (32) and the CORONA trial (33) tested the effects of
statin therapy in patients with chronic heart failure and did
not demonstrate any influence on the hard end-points.
Therefore, even if statins have a positive influence on the
renal function of patients with heart failure, an effect on the
overall prognosis is unlikely.
Adenosine A1 receptor antagonists. Stimulation of the
adenosine A1 receptor on the glomerular afferent arteriole
reduces renal blood flow and the glomerular filtration rate
(GFR), and also increases sodium and water reabsorption
through the stimulation of receptors on the proximal tubules.
Adenosine receptor antagonists, such as aminophylline and
theophylline, have been used in heart failure patients, but
arrhythmic effects have hampered their use. Recently, the
PROTECT trial tested the effects of rolofylline as a renal
protective strategy in 2,033 patients with acute heart failure,
and the results indicated no effect of rolofylline in this setting
(34).
Xanthine oxidase inhibitors. Data derived from experi-
mental and clinical models have suggested that xanthine
oxidase inhibitors have positive metabolic effects in the
failing myocardium that provide increases in energy
delivered by adenosine triphosphate (35). In a small study
of patients with ischemic cardiomyopathy, a single
intravenous dose of 400 mg of oxypurinol led to a
Figure 2 - Prevention strategies for renal dysfunction according to the heart failure stage.
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reduction in end-systolic volume and an increased left
ventricular ejection fraction relative to the placebo. In
patients with chronic kidney disease (36), the use of
allopurinol has been associated with a reduction in
cardiovascular events and increases in the GFR (37,38).
However, the effects of allopurinol for renal protection in
patients with heart failure are still under discussion. Xanthine
oxidase-derived reactive oxygen species accumulation leads
to nitric oxide scavenging and endothelial dysfunction but
also to various other detrimental metabolic, functional and
immunologic effects. Novel data are emerging to suggest
direct effects of uric acid on immune stimulation and
metabolic interference (39).
Renin inhibitors. Despite the current availability of
medical treatments for heart failure, the residual rates of
hospitalization and death remain high. One putative
explanation for these high rates is insufficient RAAS
inhibition produced by the triggering of counterregulatory
mechanisms of renin release by single-site RAS blockade.
Therefore, the use of a specific inhibitor of human renin,
such as aliskiren, has been proposed. Aliskiren was tested in
addition to ACE inhibitors or ARBs in patients with diabetes
mellitus and renal dysfunction; however, an increase in
adverse events (increased incidence of renal complications,
hyperkalemia, hypotension and non-fatal strokes) and no
apparent benefits among the patients randomized to
aliskiren prompted the data safety and monitoring board
for the study to recommend its termination. Subsequently,
the ASPIRE study reported a significant increase in the risk
of renal failure, hypotension and hyperkalemia with the
combination of aliskiren and an ACE inhibitor or ARB in
high-risk post-myocardial infarction patients (40). Ongoing
trials will evaluate the effects of aliskiren on the prognosis,
ventricular function and renal function in the setting of
chronic (41) and acute heart failure (42).
Renal denervation. Hyperactivation of the SNS is
involved in the pathophysiology of hypertension, renal
insufficiency and heart failure. Devices have been
developed for ablation of the renal sympathetic nerves by a
radiofrequency-emitting catheter inserted percutaneously
into the femoral artery in the groin and consecutively
advanced to lie in the lumen of each renal artery.
Sympathetic nerves enter the human kidneys through the
walls of the renal arteries and are thus within reach of the
ablative energy. This type of intervention has been reported
to be successful in patients with resistant hypertension (43).
Renal function, as assessed by serum creatinine, eGFR and
cystatin C concentrations, was unchanged from the baseline
in both groups at 6 months. Several ongoing clinical trials are
investigating the safety and efficacy of renal denervation in
patients with CHF, and its application as a preventive
measure for renal dysfunction remains speculative (44).
Low-dose dopamine. The infusion of low-dose dopa-
mine (4-5 mg kg-1min-1) has been shown to induce renal
vasodilation and natriuresis mediated by the stimulation of
the dopamine alpha-1 and alpha-2 receptors in the proximal
tubule, the thick ascending loop of Henle and the cortical
collecting ducts (45). In addition, putative renoprotective
effects of dopamine have also been suggested in various
clinical settings. In a meta-analysis of 61 trials that randomly
assigned 3,359 patients at risk for acute renal failure to
receive low-dose dopamine or placebo, dopamine was
associated with a 24% increase in urine output, 4%
relative decrease in serum creatinine level and 6% relative
increase in measured creatinine clearance (46). In patients
with systolic heart failure, low-dose dopamine has also been
demonstrated to increase renal blood flow and the GFR. In a
clinical trial with 60 patients with acute decompensated
heart failure, the combination of infused low-dose
furosemide and low-dose dopamine was suggested to be
as effective as a high-dose furosemide infusion in terms of
the clinical and diuretic response and to be associated with a
significantly lower rate of worsening renal function, which
suggests a renoprotective effect in this patient population
(47). The long-term effects of this intervention in a larger
population of patients are yet to be determined.
Diuretics. Despite the scarce evidence based on
prospective data and clinical trials, diuretics have long been a
mainstay in the treatment of episodes of acute decompensated
heart failure in the presence of congestive phenomena.
Concerns regarding diuretic use involve ototoxicity, hy-
pocalcemia and diuretic-induced hypovolemia; these
conditions become particularly important in the setting of
ADHF because of the presence of hypotension, right
ventricular failure and elevated intra-abdominal pressure as
well as the use of high diuretic doses. Thus, a renoprotective
strategy could potentially be derived from the continuous
infusion of smaller doses of a diuretic. Different diuretic
strategies were tested in a clinical trial (48) that assigned
patients with acute decompensated heart failure to receive
furosemide administered intravenously in a bolus every
12 hours or by continuous infusion and at a low or high
dose; the authors concluded that there were no significant
differences in the change in renal function when diuretic
therapy was administered by bolus compared with continuous
infusion or at a high dose compared with a low dose.
Human recombinant B-type natriuretic peptide. Ne-
siritide is a systemic pulmonary vasodilator that is capable
of promoting natriuresis and diuresis and of inhibiting the
RAAS. Initial experiments in patients without heart failure
and outpatients with stable heart failure produced con-
flicting results regarding the effect of nesiritide on the GFR,
with some studies suggesting an improvement in the GFR
and others showing no impact (49,50,51). Later, a meta-
analysis found that treatment with nesiritide was associated
with worsened renal function (52). A clinical trial with 75
patients with acute decompensated heart failure showed
that nesiritide had no impact on renal function (53).
Recently, a larger clinical trial with 7,141 patients
confirmed that nesiritide had a neutral effect on renal
function but was associated with an increase in the rate of
hypotension (54). These findings do not warrant the use of
nesiritide as a renoprotective measure in patients with
ADHF. Other similar molecules, such as alpha-human atrial
natriuretic peptide (carperitide), are currently under
investigation.
Calcium sensitizers. This class of drugs includes
inotropic agents, such as levosimendan, that also produce
arterial and venous vasodilation through the activation of
ATP-sensitive potassium channels. Because central venous
pressure is an independent predictor of the GFR in patients
with heart failure, levosimendan has been proposed as an
agent that may be associated with improved renal function
(55). Thus, levosimendan infusion has been described to
improve the GFR more than infusion of dobutamine, even
though both treatment regimens were associated with an
increase in urine output (56). Another study suggested a
sustained improvement in renal function up to 3 months
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after infusion in patients with advanced heart failure
eligible for heart transplantation (57). In the LIDO trial,
levosimendan showed greater improvement of serum
creatinine levels than dobutamine (58). However, the use
of levosimendan in patients with ADHF has been hampered
by the results of more recent clinical trials: in SURVIVE (59),
the primary endpoint of total mortality was not different
between levosimendan and dobutamine; in REVIVE-II (60),
the combined clinical endpoint including mortality and
symptoms did indicate a benefit of levosimendan over a
placebo. Even if the putative beneficial effects of
levosimendan on renal function are confirmed, the
positive effects on renal blood flow may be offset by the
drop in blood pressure and risk of arrhythmia.
Ultrafiltration. Ultrafiltration (UF) has been proposed as
an alternative to diuretics to obtain faster relief of
pulmonary/systemic congestion. This method consists of
an extracorporeal circuit through which blood is pumped
from a venous access into the filter, to be then returned into
the patient (61). During IU, water crosses the semipermeable
membrane in the filter by ultrafiltration, which is a process
driven by the hydrostatic pressure difference across the
filter membrane. Small solutes that pass through the
ultrafiltration membrane, such as electrolyte, are removed
concurrently. Thus, UF offers isotonic removal and
maintains the plasma concentration of low-molecular-
weight solutes such as sodium and other small solutes.
Most of the expected clinical benefit is provided by fluid
removal and improvement of pulmonary/systemic
congestion; however, neither significant correction of
hyponatremia, azotemia, hypo/hyperkalemia or metabolic
acidosis/alkalosis, nor a significant removal of high-
molecular-weight substances (such as myocardial-
depressant factors and cytokines) can be expected.
The UNLOAD trial (62) compared UF with diuretic
therapy in patients with ADHF; UF produced greater
weight loss and a more negative fluid balance and was
associated with a reduced readmission rate. However,
patients with hypotension, hemodynamic instability or
under vasoactive inotropes were excluded; additionally,
no improvement in neurohormonal activation accompanied
the fluid removal and weight change. Data on the effects of
UF on renal function in heart failure are lacking; small
observational studies showed no changes in serum creati-
nine when UF was compared to diuretics in patients with
chronic heart failure (63), and in a small case series, 45% of
patients underwent hemodialysis during the same or a
subsequent hospitalization after UF (64). Thus far, there is
no indication that the use of UF in patients with ADHF may
prevent the occurrence of renal dysfunction.
Arginine vasopressin receptor antagonists. Tolvaptan
was compared with a placebo in a randomized, double-
blind trial involving 254 patients with chronic heart failure.
When added to standard heart failure therapy, tolvaptan
was associated with significant weight reduction secondary
to fluid loss relative to the placebo. Among 70 patients with
hyponatremia, tolvaptan was associated with improved and
often normalized serum sodium concentrations. The Acute
and Chronic Therapeutic Impact of a Vasopressin
Antagonist in Congestive Heart Failure trial (ACTIV in
CHF) was a multicenter, randomized, double-blind,
placebo-controlled, parallel-group, dose-ranging phase II
feasibility trial that compared three once-daily doses of
tolvaptan with a placebo in patients with worsening heart
failure symptoms. Sixty-eight patients (21.3%) had
hyponatremia at randomization. All doses of tolvaptan
significantly reduced body weight 24 hours after the first
dose, with significant increases in urine volume relative to
the placebo. Significant hemodynamic changes and
significant differences in the 60-day rehospitalization rate,
unscheduled visits for heart failure and deaths were not
noted between patients treated with tolvaptan and those
treated with the placebo. These preliminary findings in
patients with heart failure led to the large, multicenter,
international Efficacy of Vasopressin Antagonism in Heart
Failure Outcome Study with Tolvaptan (EVEREST). This
trial was a combination of three studies: two were
identically designed to investigate short-term effects on
global clinical status and symptoms in patients with heart
failure, and the third study was designed to analyze all
randomized patients to evaluate outcomes, including time
to all-cause mortality and time to first cardiovascular
mortality or hospitalization for heart failure. EVEREST
was a randomized, double-blind, placebo-controlled study
that enrolled 4,133 hospitalized patients with symptomatic
left ventricular systolic dysfunction (left ventricular ejection
fraction #40%). The patients were randomized to 30 mg of
tolvaptan or a placebo once a day for 60 days in addition to
their standard heart failure regimen. The results indicated a
significant improvement in patient-assessed dyspnea on
day 1 in the tolvaptan group relative to the group receiving
the placebo. This improvement in dyspnea could be related
to the significant reduction in body weight secondary to
aquaresis recorded on day 1 in patients receiving tolvaptan
relative to the patients receiving the placebo. Overall,
tolvaptan had no effect on all-cause mortality. Similarly,
no significant difference in the composite measure of death
from cardiovascular causes or hospitalization for heart
failure was detected between the tolvaptan and placebo
groups (65,66,67).
Hypertonic saline solution. Hypertonic saline solutions
have been studied in different forms of cardiovascular
collapse since 1917 (68), and data from experimental shock
models demonstrate that the infusion of 7.5% NaCl
produces vasodilatation and increased regional blood flow
to the coronary (69), renal (70), intestinal and skeletal muscle
(71) circulation. Additionally, hypertonic saline improves
renal function and myocardial contractility, probably
because of a direct cardiac inotropic effect induced by
hypertonicity (72,73). In patients, the infusion of 7.5% NaCl
has been successfully used in cardiogenic shock arising
from right ventricular infarction (74). Small volumes of
saline solutions have also been tested in patients with heart
failure (75,76), and most studies have focused on the aspects
of safety and effectiveness. A randomized trial reported, as
a secondary finding in a selective population of patients
highly resistant to diuretics, that the infusion of saline
solutions with different tonicities was associated with lower
creatinine levels (77). However, few previous studies
specifically examined the effects of a saline solution on
renal function in patients with decompensated heart failure.
Recently, hypertonic saline solution administration was
reported to attenuate heart failure-induced kidney
dysfunction as indicated by improvement in the renal
glomerular filtration rate (as measured by serum cystatin C
and creatine levels) and tubular function (as measured by
the expression of renal tubular proteins aquaporin 2, NHE3
and urea transporter 1). These data indicate that hypertonic
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saline is a promising low-cost therapeutic strategy in
patients with decompensated heart failure that warrants
further investigation.
& CONCLUSIONS
Despite recent improvements in the understanding of
pathophysiological phenomena and in diagnostic tools,
therapies targeted towards the prevention of renal dysfunc-
tion in patients with heart failure are still lacking.
Interventions aimed at pivotal pathophysiological points
and administered early during the course of the disease may
provide better results. However, prospective data in larger
populations for most of the new, currently available
strategies are still needed.
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